JP2021503891A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021503891A5 JP2021503891A5 JP2020528047A JP2020528047A JP2021503891A5 JP 2021503891 A5 JP2021503891 A5 JP 2021503891A5 JP 2020528047 A JP2020528047 A JP 2020528047A JP 2020528047 A JP2020528047 A JP 2020528047A JP 2021503891 A5 JP2021503891 A5 JP 2021503891A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- acid sequence
- heavy chain
- light chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762589809P | 2017-11-22 | 2017-11-22 | |
| US62/589,809 | 2017-11-22 | ||
| PCT/IB2018/059143 WO2019102353A1 (en) | 2017-11-22 | 2018-11-20 | Reversal binding agents for anti-factor xi/xia antibodies and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021503891A JP2021503891A (ja) | 2021-02-15 |
| JP2021503891A5 true JP2021503891A5 (https=) | 2022-01-04 |
Family
ID=64661419
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020528047A Pending JP2021503891A (ja) | 2017-11-22 | 2018-11-20 | 抗第ＸＩ／ＸＩａ因子抗体に対する反転結合剤およびそれらの使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20200308301A1 (https=) |
| EP (1) | EP3713965A1 (https=) |
| JP (1) | JP2021503891A (https=) |
| KR (1) | KR20200087236A (https=) |
| CN (1) | CN111902427A (https=) |
| AU (1) | AU2018372135A1 (https=) |
| BR (1) | BR112020010016A2 (https=) |
| CA (1) | CA3083210A1 (https=) |
| WO (1) | WO2019102353A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL267538B2 (en) | 2016-12-23 | 2024-05-01 | Novartis Ag | Antibodies against factor XI and methods for use in preventing, treating, managing or reducing the risk of thromboembolic disorder or stroke in a patient |
| EP3873944A1 (en) * | 2018-10-31 | 2021-09-08 | Bayer Aktiengesellschaft | Reversal agents for neutralizing the therapeutic activity of anti-fxia antibodies |
| EP3898700A1 (en) * | 2018-12-18 | 2021-10-27 | Novartis AG | Reversal binding agents for anti-factor xi/xia antibodies and uses thereof |
| BR112022012064A2 (pt) * | 2019-12-20 | 2022-08-30 | Anthos Therapeutics Inc | Formulação de distribuição de fármaco intravenosa, frasco compreendendo a mesma e método de tratamento de um sujeito acometido por ou em risco de desenvolver um distúrbio tromboembólico |
| CU20230031A7 (es) * | 2020-12-18 | 2024-02-07 | Anthos Therapeutics Inc | Método para la detección de anticuerpos antifármaco contra anticuerpos de factor xi y/o factor xia |
| IL311801A (en) * | 2021-11-18 | 2024-05-01 | Anthos Therapeutics Inc | Dosage regimen of factor XI/XIA antibodies |
| CN118382643A (zh) * | 2022-01-05 | 2024-07-23 | 上海迈晋生物医药科技有限公司 | 一种包含抗FXI/FXIa抗体的药物组合物及其用途 |
| TW202405022A (zh) * | 2022-06-24 | 2024-02-01 | 美商安瑟斯治療公司 | 與抗因子ｘｉ／因子ｘｉａ抗體之組合療法 |
| EP4644426A1 (en) * | 2022-12-30 | 2025-11-05 | Gan & Lee Pharmaceuticals Co., Ltd. | Antibody against coagulation factor xi and/or activated form factor xia thereof, and use thereof |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| EP1291360A1 (en) | 1991-12-13 | 2003-03-12 | Xoma Corporation | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| WO1993022332A2 (en) | 1992-04-24 | 1993-11-11 | Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
| AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
| SE9400088D0 (sv) | 1994-01-14 | 1994-01-14 | Kabi Pharmacia Ab | Bacterial receptor structures |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| EP1958962A3 (en) | 1997-06-12 | 2013-05-01 | Novartis International Pharmaceutical Ltd. | Artificial antibody polypeptides |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| ES2434961T5 (es) | 1998-04-20 | 2018-01-18 | Roche Glycart Ag | Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| HU230769B1 (hu) | 1999-01-15 | 2018-03-28 | Genentech Inc. | Módosított effektor-funkciójú polipeptid-változatok |
| EP1176195B1 (en) | 1999-04-09 | 2013-05-22 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| DE19932688B4 (de) | 1999-07-13 | 2009-10-08 | Scil Proteins Gmbh | Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen |
| ES2327382T3 (es) | 1999-07-20 | 2009-10-29 | Morphosys Ag | Metodos para presentar (poli)peptidos/proteinas en particulas de bacteriofagos a traves de enlaces disulfuro. |
| AT411997B (de) * | 1999-09-14 | 2004-08-26 | Baxter Ag | Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate |
| US20050053973A1 (en) | 2001-04-26 | 2005-03-10 | Avidia Research Institute | Novel proteins with targeted binding |
| US20050048512A1 (en) | 2001-04-26 | 2005-03-03 | Avidia Research Institute | Combinatorial libraries of monomer domains |
| US20040175756A1 (en) | 2001-04-26 | 2004-09-09 | Avidia Research Institute | Methods for using combinatorial libraries of monomer domains |
| EP1421203A4 (en) | 2001-05-17 | 2005-06-01 | Diversa Corp | NEW ANTIGEN-BINDING MOLECULES FOR THERAPEUTIC, DIAGNOSTIC, PROPHYLACTIC, ENZYMATIC, INDUSTRIAL AND AGRICULTURAL APPLICATIONS AND METHOD FOR THE PRODUCTION AND SCREENING THEREOF |
| HUP0600342A3 (en) | 2001-10-25 | 2011-03-28 | Genentech Inc | Glycoprotein compositions |
| AU2003217912A1 (en) | 2002-03-01 | 2003-09-16 | Xencor | Antibody optimization |
| DE10324447A1 (de) | 2003-05-28 | 2004-12-30 | Scil Proteins Gmbh | Generierung künstlicher Bindungsproteine auf der Grundlage von Ubiquitin |
| JP4782700B2 (ja) | 2004-01-20 | 2011-09-28 | カロバイオス ファーマシューティカルズ インコーポレイティッド | 最低限必須な結合決定基を用いた抗体特異性の移入 |
| US20060008844A1 (en) | 2004-06-17 | 2006-01-12 | Avidia Research Institute | c-Met kinase binding proteins |
| PT3002298T (pt) * | 2007-11-21 | 2019-11-20 | Univ Oregon Health & Science | Anticorpos monoclonais anti-fator xi e métodos de utilização dos mesmos |
| WO2009154461A1 (en) | 2008-06-19 | 2009-12-23 | Prothix Bv | Use of anti-factors xi antibodies for prevention of thrombus formation |
| US8388959B2 (en) | 2008-12-18 | 2013-03-05 | Oregon Health & Science University | Anti-fXI antibodies and methods of use |
| PL3604510T3 (pl) * | 2009-03-30 | 2025-07-28 | Alexion Pharmaceuticals, Inc. | Antidota na inhibitory czynnika xa i sposoby ich stosowania |
| EP2847228B1 (en) | 2012-05-10 | 2018-07-25 | Bayer Pharma Aktiengesellschaft | Antibodies capable of binding to the coagulation factor xi and/or its activated form factor xia and uses thereof |
| UY36751A (es) * | 2015-06-26 | 2017-01-31 | Novartis Ag | Anticuerpos de factor xi y métodos de uso |
| WO2017015619A1 (en) * | 2015-07-23 | 2017-01-26 | The Regents Of The University Of California | Antibodies to coagulation factor xia and uses thereof |
| TW201802121A (zh) * | 2016-05-25 | 2018-01-16 | 諾華公司 | 抗因子XI/XIa抗體之逆轉結合劑及其用途 |
-
2018
- 2018-11-20 KR KR1020207017415A patent/KR20200087236A/ko not_active Ceased
- 2018-11-20 JP JP2020528047A patent/JP2021503891A/ja active Pending
- 2018-11-20 CA CA3083210A patent/CA3083210A1/en active Pending
- 2018-11-20 BR BR112020010016-1A patent/BR112020010016A2/pt not_active IP Right Cessation
- 2018-11-20 EP EP18815811.7A patent/EP3713965A1/en not_active Withdrawn
- 2018-11-20 CN CN201880087024.1A patent/CN111902427A/zh active Pending
- 2018-11-20 WO PCT/IB2018/059143 patent/WO2019102353A1/en not_active Ceased
- 2018-11-20 AU AU2018372135A patent/AU2018372135A1/en not_active Abandoned
- 2018-11-20 US US16/765,274 patent/US20200308301A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021503891A5 (https=) | ||
| Loof et al. | The role of coagulation/fibrinolysis during Streptococcus pyogenes infection | |
| TWI861458B (zh) | 用於治療各種疾病和病症的抑制masp-3的組合物和方法 | |
| JP2017113019A5 (https=) | ||
| JPH06502307A (ja) | 血液凝固タンパク質のアンタゴニストおよびその利用方法 | |
| US7422890B2 (en) | Therapeutic and prophylactic agents and methods of using the same | |
| JP2015503909A5 (https=) | ||
| JP2019505527A5 (https=) | ||
| JPH0784392B2 (ja) | 第Ｘａ因子含有抗凝固剤組成物 | |
| ES2283308T3 (es) | Anticuerpo monoclonal para el factor viii, que incluso cuando esta presente en exceso molar inactiva el factor viii solo en parte y metodo para producir dicho anticuerpo. | |
| JP2019528285A5 (https=) | ||
| BR112019012667A2 (pt) | Anticorpos do fator xi e métodos de uso | |
| TW202039586A (zh) | 抗因子XI/XIa抗體之逆轉結合劑及其用途 | |
| EP1825864A2 (en) | Antithrombotic agents | |
| AU2015264550B2 (en) | Ang2 antibodies | |
| WO1994009034A1 (en) | Clot directed anticoagulant, process for making same and methods of use | |
| ES2346189T3 (es) | Metodo y composicion farmaceutica para prevenir y/o tratar el sindrome de respuesta inflamatoria generalizada. | |
| Liou et al. | Acute thrombotic microangiopathy and cortical necrosis following administration of alemtuzumab: a case report | |
| CN101891820A (zh) | 人源化抗人血管性血友病因子单克隆抗体及其应用 | |
| WO2003013423A2 (en) | Antithrombotic agent | |
| Cicardi et al. | The deficiency of C1 inhibitor and its treatment | |
| CN107043423B (zh) | 凝血酶抗体、其抗原结合片段及医药用途 | |
| TOCHIMARU et al. | Current topics in childhood lupus nephritis | |
| Vande Vusse et al. | Prohemostatic therapy: the rise and fall of aprotinin | |
| WO2026017000A1 (zh) | 一类具有抗血管性血友病因子效应的单克隆抗体及其用途 |